Yunnan Baiyao Group Co Ltd, a household name in China's pharmaceutical sector, has, over the last five years, pursued diversification, innovation and financial stability, positioning itself among the most competitive players in the industry. Now, the company looks to continue to expand its presence in traditional Chinese medicine and the wider healthcare market.

Best known for its century-old TCM products, in 2024, Yunnan Baiyao's aerosol sprays, plasters, medicated bandages, toothpaste, and Panax notoginseng extracts maintained leading market shares in their respective categories. Notably, its flagship aerosol spray product achieved sales revenue exceeding 2.1 billion yuan ($294.78 million), marking a 26 percent year-on-year increase. Additionally, Yunnan Baiyao toothpaste has consistently led the Chinese market in terms of all-channel market share.

At the same time, the company has concentrated on its core business and deepening its roots in the pharmaceutical industry. It actively promotes the "TCM + Big Health" strategy under the 14th Five-Year Plan (2021-25), driving business development and performance growth.

Alongside its consumer-facing brands, the company has steadily invested in securing supply chain quality. It has built a full industrial chain for TCM resources, from planting to processing, as well as distribution to ensure safety and consistency.

The company has utilized technologies such as satellite imaging and AI-assisted procurement to monitor herb cultivation and improve sourcing. These measures, according to the company, are helping standardize upstream production and enhance the credibility of TCM in modern healthcare.